` NBIX (Neurocrine Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

NBIX
vs
S&P 500

Over the past 12 months, NBIX has underperformed S&P 500, delivering a return of -15% compared to the S&P 500's 12% growth.

Stocks Performance
NBIX vs S&P 500

Loading

Performance Gap
NBIX vs S&P 500

Loading
NBIX
S&P 500
Difference

Performance By Year
NBIX vs S&P 500

Loading
NBIX
S&P 500
Add Stock

Competitors Performance
Neurocrine Biosciences Inc vs Peers

S&P 500
NBIX
ABBV
AMGN
GILD
VRTX
Add Stock

Neurocrine Biosciences Inc
Glance View

Economic Moat
Wide
Market Cap
12B USD
Industry
Biotechnology

Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry. Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.

NBIX Intrinsic Value
135.95 USD
Undervaluation 11%
Intrinsic Value
Price
Back to Top